ReviewOncology letters2018
Tumor angiogenesis and anti-angiogenic gene therapy for cancer.
Review in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed, 3 syntheses or guidelines pooled it, 238 citations in OpenAlex.
- Angiostatin: a promising therapeutic target for atopic dermatitis.Archives of dermatological research · 2025Pooled it
- Oncologic feasibility for negative pressure wound therapy application in surgical wounds: A meta-analysis.International wound journal · 2022Pooled it
- Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis.BioMed research international · 2018Pooled it
- Photoacoustic microscopy reveals deep angiogenic responses in 3D bioprinted tumor-vessel models.Microsystems & nanoengineering · 2026Article
- Chlorogenic acid suppresses angiogenesis in 4T1 breast tumorsResearch in pharmaceutical sciences · 2026Article
- Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.Gene therapy · 2026Article
- The purinergic signaling interfaces in breast cancer angiogenesis.Purinergic signalling · 2026Review
- Erbin Inhibited AngiogenesisCurrent medicinal chemistry · 2026Article
- The Role of Angiogenesis in Breast Cancer and Obesity: Unravelling the Connection.International journal of breast cancer · 2026Review
- A Phenotype-Driven Discovery of Pro-Revascularization Chalcone Derivatives Using Zebrafish and CAM Models.Journal of toxicology · 2026Article
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Review
- The Current Role of Antiangiogenics in Colorectal Cancer.International journal of molecular sciences · 2025Review
- LCRMP-1 induces tumor angiogenesis by transcriptionally upregulating SERPINE1 in lung adenocarcinoma.Communications biology · 2025Article
- Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication.Genes & diseases · 2025Review
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Prognostic implications of complement C1q-like 4 expression in breast cancer.Scientific reports · 2025Article
- A quinoline derivative exerts antineoplastic efficacy against solid tumour by inducing apoptosis and anti-angiogenesis both in vitro and in vivo.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Efficacy and safety of anlotinib monotherapy or combination therapy in the treatment of patients with advanced non-small cell lung cancer: a retrospective real-world study conducted in East China.BMC pulmonary medicine · 2025Article
- Multi-functional near-infrared fluorescent polymer dot-siRNA for gene expression regulation.Journal of materials chemistry. B · 2025Article
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When Folkman first suggested a theory about the association between angiogenesis and tumor growth in 1971, the hypothesis of targeting angiogenesis to treat cancer was formed. Since then, various studies conducted across the world have additionally confirmed the theory of Folkman, and numerous efforts have been made to explore the possibilities of curing cancer by targeting angiogenesis. Among them, anti-angiogenic gene therapy has received attention due to its apparent advantages. Although specific problems remain prior to cancer being fully curable using anti-angiogenic gene therapy, several methods have been explored, and progress has been made in pre-clinical and clinical settings over previous decades. The present review aimed to provide up-to-date information concerning tumor angiogenesis and gene delivery systems in anti-angiogenic gene therapy, with a focus on recent developments in the study and application of the most commonly studied and newly identified anti-angiogenic candidates for anti-angiogenesis gene therapy, including interleukin-12, angiostatin, endostatin, tumstatin, anti-angiogenic metargidin peptide and endoglin silencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.